BETHESDA, MD / ACCESSWIRE / November 23, 2020 / HF Enterprises Inc. (NASDAQ:HFEN)(the "Company"), a diversified holding company principally engaged through its subsidiaries in property development, digital transformation technology and biohealth activities, today announced the pricing of its initial public offering of 2,160,000 shares of its common stock at a public offering price of $7.00 per share for gross proceeds of $15,120,000 before deducting offering expenses. In addition, the Company has granted Aegis Capital Corp. a 60-day option to purchase up to 15% of additional shares of common stock at the public offering price to cover over-allotments, if any. The shares are expected to begin trading on The Nasdaq Capital Market on November 24, 2020, under the symbol "HFEN."

Aegis Capital Corp. is acting as lead bookrunning manager.

WestPark Capital, Inc. is acting as co-manager.

A registration statement relating to the shares of common stock being sold in this offering was declared effective by the Securities and Exchange Commission (the "SEC") on November 12, 2020. The offering is being made only by means of a prospectus. Copies of the final prospectus may be obtained, when available, on the SEC's website, www.sec.gov, or by contacting Aegis Capital Corp., Attention: Syndicate Department, 810 7th Avenue, 18th Floor, New York, NY 10019, by email at syndicate@aegiscap.com, or by telephone at (212) 813-1010.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About HF Enterprises Inc.

HF Enterprises Inc. is a diversified holding company principally engaged through its subsidiaries in property development, digital transformation technology and biohealth activities with operations in the United States, Singapore, Hong Kong, Australia and South Korea. The Company manages its three principal businesses primarily through its subsidiary, Alset International Limited (formerly known as "Singapore eDevelopment Limited"), a public company traded on the Singapore Stock Exchange. Through this subsidiary (and indirectly, through other public and private U.S. and Asian subsidiaries), the Company is actively developing two significant real estate projects near Houston, Texas and in Frederick, Maryland in the property development segment. The Company has designed applications for enterprise messaging and e-commerce software platforms in the United States and Asia in the digital transformation technology business unit. The Company's recent foray into the biohealth segment primarily includes research to treat neurological and immune-related diseases, nutritional chemistry to create a natural sugar alternative, research regarding innovative products to slow the spread of disease, and certain natural foods and supplements.

Investor Contact:

Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
Dave@redchip.com

Forward-Looking Statement Disclaimer

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, including the Company's expectations regarding the proposed offering of the Company's shares of common stock, including as to the consummation of the offering described above and the size of the offering are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the SEC. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: HF Enterprises Inc.

ReleaseID: 618131

Industry Veteran Brings Deep R&D and Clinical Development Experience to Tarus

NEW YORK, NY / ACCESSWIRE / November 24, 2020 / Tarus Therapeutics Inc., an innovative biotechnology company developing adenosine receptor antagonists for cancer immunotherapy and select non-oncology indications, today announced that Dr. Brian Schwartz, M.D. has joined the company as Acting Chief Medical Officer and Head of the Scientific Advisory Board (SAB).

Dr. Schwartz was Chief Medical Officer at ArQule from 2008, and also Head of Research & Development from 2013, until the company's acquisition by Merck in 2020 for $2.7 billion. Dr. Schwartz has extensive experience in the pharmaceutical and biotechnology industries. Prior to joining ArQule, he was Chief Medical Officer and Senior Vice President, Clinical and Regulatory Affairs, at Ziopharm Oncology where he built and led the clinical, regulatory, and quality assurance departments with responsibilities for the development of new cancer drugs. Prior to Ziopharm, Dr. Schwartz held a number of leadership positions at Bayer Healthcare. At Bayer, Dr. Schwartz was a key physician responsible for the global clinical development of sorafenib (Nexavar®) and led the clinical team through a successful Phase 3 trial in renal cell cancer, leading to U.S. Food and Drug Administration (FDA) approval. He has extensive regulatory experience working with the FDA's Oncology Division, the European Medicines Agency (EMA), and numerous other health authorities. Dr. Schwartz has been involved in multiple clinical and regulatory activities, including Phase 4 studies and interactions with the National Cancer Institute and other oncology cooperative groups. Dr. Schwartz received his medical degree from the University of Pretoria, South Africa, practiced medicine, and worked at the University of Toronto prior to his career in industry. Dr. Schwartz serves on the Boards of Mereo Pharma Group Plc, LifeSci Acquisition Corp and Enlivex Therapeutics Ltd. He is also an advisor to the California Institute of Regenerative Medicine and Pontifax Venture Capital.

"With our IND submissions for multiple programs and indications expected in the near term, Tarus is positioned to rapidly expand its focus on clinical development," said Sushant Kumar, Ph.D., Chief Executive Officer of Tarus Therapeutics. "We are delighted to welcome Dr. Schwartz to Tarus' s leadership team. Dr. Schwartz's deep insight and expertise in clinical development of oncology drugs will be invaluable as we execute our clinical strategy," added Dr. Kumar.

"I am excited to join the Tarus team and look forward to overseeing its research programs and leading the clinical development of multiple programs focused on adenosine receptor antagonism, a promising new area in immuno-oncology," said Dr. Schwartz.

About Tarus Therapeutics Inc.

Tarus is developing small molecule inhibitors of A2AR, A2BR, and Dual A2AR/A2BR inhibitors for cancer immunotherapy and select non-oncology indications. The Company has the most comprehensive portfolio of adenosine receptor antagonists in development, with both first-in-class and best-in-class programs. More information can be found at www.tarustx.com.

Contact:

Tarus Therapeutics, Inc.
Sushant Kumar, PhD
President & CEO
info@tarustx.com

SOURCE: Tarus Therapeutics

ReleaseID: 618007

GENEVA, SWITZERLAND and RADNOR, PA / ACCESSWIRE / November 24, 2020 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief" or the "Company") and NeuroRx, Inc., announced that more than 175 patients with Critical COVID-19 and Respiratory Failure who also have a severe comorbidity have now been entered into an Expanded Access Protocol (EAP) with RLF-100(TM) in the United States.

All patients had severe comorbidities (such as organ transplant, recent heart attack, and cancer) that rendered them ineligible for the ongoing randomized, controlled phase 2b/3 trial being conducted to ascertain safety and efficacy of RLF-100(TM), and all patients were deteriorating despite treatment with approved therapies for COVID-19 (see www.clinicaltrials.gov NCT 04311697). Of the 90 patients who have so far reached 28 days of follow-up, 72% survived to day 28.

As previously reported by Youssef and coworkers (http://dx.doi.org/10.2139/ssrn.3665228), at Houston Methodist Hospital, 21 patients treated with RLF-100(TM) under the EAP were compared to 24 control patients treated in the same setting. Only 17% of the control patients, all treated with best available intensive care unit (ICU) Standard of Care, survived to day 28. The survival rate with RLF-100(TM) reported today is comparable to that seen among the open-label patients treated with RLF-100(TM) by Youssef et al. Despite advancements in treating COVID-19, survival for the patients at highest risk due to severe comorbidities has remained dismal in the absence of an effective therapy.

Notably, in the EAP, no drug-related Serious Adverse Events have been reported to date among these patients nor the 160 patients randomized to RLF-100(TM) vs. placebo in the U.S. phase 2b/3 clinical trial currently underway. Thus, from a risk/benefit perspective, while the benefit of RLF-100(TM) has not yet been proven in a randomized prospective trial, no serious risk has been identified so far.

Currently, 25 U.S. hospitals have enrolled patients in the EAP, nearly all of which are community hospitals, suggesting that RLF-100(TM) can demonstrate effectiveness in the hands of front-line physicians who deliver the majority of care to patients with Critical COVID-19. Physicians enrolling patients in the EAP have routinely reported that initial patients at their sites have frequently been in the ICU for several weeks without recovery prior to treatment with RLF-100(TM). As patients are treated earlier in the course of their ICU stay, there is an emerging clinical impression that RLF-100(TM) has an even greater impact on recovery.

"We are reassured that emerging real-world data on the use of RLF-100(TM) in improving survival in patients with Critical COVID-19 are comparable to results seen in the hands of major academic teaching centers. We hope that these findings are viewed as encouraging at a time when many Americans, including the doctors, nurses, and other front-line caregivers who are the heart of our initiative, are celebrating the Thanksgiving holiday at a distance from their loved ones. We look forward to completing enrollment and reporting the results of our pivotal U.S. clinical trial," said Prof. Jonathan C. Javitt, MD, MPH, CEO and founder of NeuroRx, Inc.

ABOUT VIP IN LUNG INJURY
Vasoactive Intestinal Polypeptide (VIP) was first discovered by the late Dr. Sami Said in 1970. Although first identified in the intestinal tract, VIP is now known to be produced throughout the body and to be primarily concentrated in the lungs. VIP has been shown in more than 100 peer-reviewed studies to have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation. Most importantly, 70% of the VIP in the body is bound to a rare cell in the lung, the alveolar type 2 cell, that is critical to transmission of oxygen to the body. VIP has a 20-year history of safe use in humans in multiple human trials for sarcoidosis, pulmonary fibrosis, asthma/allergy, and pulmonary hypertension.

COVID-19-related death is primarily caused by respiratory failure. Before this acute phase, however, there is evidence of early viral infection of the alveolar type 2 cells. These cells are known to have angiotensin converting enzyme 2 (ACE2) receptors at high levels, which serve as the route of entry for the SARS-CoV-2 into the cells. Coronaviruses are shown to replicate in alveolar type 2 cells but not in the more numerous type 1 cells. These same type 2 alveolar cells have high concentrations of VIP receptors on their cell surfaces giving rise to the hypothesis that VIP could specifically protect these cells from injury.

Injury to the type 2 alveolar cells is an increasingly plausible mechanism of COVID-19 disease progression (Mason 2020). These specialized cells replenish the more common type 1 cells that line the lungs. More importantly, type 2 cells manufacture surfactant that coats the lung and are essential for oxygen exchange. Other than RLF-100(TM), no currently proposed treatments for COVID-19 specifically target these vulnerable type 2 cells.

ABOUT RLF-100(TM)
RLF-100(TM) (Aviptadil) is a formulation of Vasoactive Intestinal Polypeptide (VIP) that was developed based on Dr. Sami Said's original work at Stony Brook University, for which Stony Brook was awarded an FDA Orphan Drug Designation in 2001. VIP is known to be highly concentrated in the lungs, where it inhibits coronavirus replication, blocks the formation of inflammatory cytokines, prevents cell death, and upregulates the production of surfactant. FDA has now granted IND authorization for intravenous and inhaled delivery of RLF-100(TM) for the treatment of COVID-19 and awarded Fast Track designation. RLF-100(TM) is being investigated in two placebo-controlled US Phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Since July 2020, more than 150 patients with Critical COVID-19 and Respiratory Failure have been treated with RLF-100(TM) under FDA-approved protocols. Information on the RLF-100(TM) Expanded Access program is at https://www.neurorxpharma.com/our-services/rlf-100.

ABOUT RELIEF THERAPEUTICS HOLDING AG
Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Relief holds orphan drug designations from the U.S. FDA and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief also holds a patent issued in the U.S. and multiple other countries covering potential formulations of RLF-100(TM).

RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on the OTCQB under the symbol RLFTF.

ABOUT NEURORX INC.
NeuroRx draws upon more than 100 years of collective drug development experience and is led by former senior executives of Johnson & Johnson, Eli Lilly, Pfizer, and AstraZeneca, PPD. In addition to its work on RLF-100(TM), NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 in suicidal bipolar depression and is currently in Phase 3 trials. Its executive team is led by Prof. Jonathan C. Javitt, MD, MPH, who has served as a health advisor to four Presidential administrations and worked on paradigm-changing drug development projects for Merck, Allergan, Pharmacia, Pfizer, Novartis, and Mannkind, together with Robert Besthof, MIM, who served as the Global Vice President (Commercial) for Pfizer's Neuroscience and Pain Division. Its Board of Directors and Advisors includes Hon. Sherry Glied, former Assistant Secretary, U.S. Dept. of Health and Human Services; Mr. Chaim Hurvitz, former President of the Teva International Group, Lt. Gen. HR McMaster, the 23rd National Security Advisor, Wayne Pines, former Associate Commissioner of the U.S. Food and Drug Administration, Judge Abraham Sofaer, and Daniel Troy, former Chief Counsel, U.S. Food and Drug Administration.

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, NeuroRx, Inc. and their businesses. The results reported herein may or may not be indicative of the results of future and larger clinical trials for RLF-100(TM) for the treatment of COVID-19. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG and/or NeuroRx, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

CORPORATE CONTACT
RELIEF THERAPEUTICS Holding AG
Raghuram (Ram) Selvaraju, Ph.D., MBA
Chairman of the Board
Mail: contact@relieftherapeutics.com
www.relieftherapeutics.com

NeuroRx, Inc.
Jonathan C. Javitt, M.D., MPH
Chairman and Chief Executive Officer
Mail: ceo@neurorxpharma.com

MEDIA CONTACT:
Relief (Europe)
MC Services AG
Anne Hennecke / Brittney Sojeva
Tel.: +49 (0) 211-529-252-14
Mail: relief@mc-services.eu

NeuroRx (United States)
David Schull
Russo Partners, LLC
Tel.: +1 (0) 858-717-2310
Mail: david.schull@russopartnersllc.com

INVESTOR RELATIONS
Relief (Europe)
MC Services AG
Anne Hennecke / Brittney Sojeva
Tel.: +49 (0) 211-529-252-14
Mail: relief@mc-services.eu

NeuroRx (United States)
Brian Korb
Solebury Trout
Tel.: +1 (0) 917-653-5122
Mail: bkorb@troutgroup.com

SOURCE: Relief Therapeutics Holdings AG via EQS Newswire

ReleaseID: 618165

Implements New Corporate Strategy to Focus on Precision Therapeutics for the Treatment of Cancer
Strengthens Pipeline by Acquiring a Proprietary Portfolio of Novel Adenosine Immuno-Modulator Compounds
Increased Cash Runway by Securing $500,000 of Gross Proceeds From an Existing Institutional Investor in October 2020

WESTLAKE VILLAGE, CA / ACCESSWIRE / November 24, 2020 / Inspyr Therapeutics, Inc. (OTC PINK:NSPX), a pharmaceutical company focused on the research and development of novel targeted precision therapeutics for the treatment of cancer, today reported its financial results for the third quarter ended September 30, 2020.

Business Highlights

During the third quarter, the company continued to execute on implementing a new corporate strategy by strengthening its portfolio and securing additional capital to pursue long-term strategic objectives and create value for stakeholders.
In October 2020, we sold additional convertible debentures resulting in $500,000 from existing investors.
In October 2020, we announced that the company would strengthen its strategic collaboration with Ridgeway Therapeutics by reacquiring its novel immune-oncology precision targeting platform for the treatment of cancer through the cancellation of our prior licensing agreement.
Inspyr and Ridgeway will pursue the research and development of RT-AR001, a potential first-in-class adenosine receptor modulator. The novel delivery technology is differentiated by its microparticle formulation that allows for better tumor infiltration and enhanced outcomes when administered intra-tumorally and has demonstrated delayed tumor growth, reduced metastases and enhanced anti-tumor immune activities in pre-clinical studies.

The company is now in the process of commencing corporate operations including: pre-clinical research and development, manufacturing, regulatory and business development. The company is dedicated to continuing to execute its new corporate strategy and will provide timely updates to shareholders.

Financial Results for the Quarter Ended September 30, 2020
Cash Position and Liquidity: At September 30, 2020, cash was approximately $33,000 as compared to approximately $116,000 at June 30, 2020.

Operating Loss: Operating loss for the quarter ended September 30, 2020 and the comparable period in 2019 were both $137,000. For the nine-month period ended September 30, 2020, the operating loss was approximately $377,000 versus $499,000 for the nine months ended September 30, 2019. The decrease in operating loss for 2020 was primarily due to a decrease in professional fees.

INSPYR THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)

 
September 30,
 
 
December 31,
 

 
2020
 
 
2019
 

 
(Unaudited)
 
 
 
 

ASSETS

Current assets:

Cash

 
$
4
 
 
$
4
 

Restricted cash

 
 
29
 
 
 
19
 

Total current assets

 
 
33
 
 
 
23
 

Total assets

 
$
33
 
 
$
23
 

LIABILITIES AND STOCKHOLDERS' DEFICIT

Current liabilities:

Accounts payable

 
$
2,330
 
 
$
2,269
 

Accrued expenses

 
 
1,940
 
 
 
1,866
 

Convertible debentures

 
 
2,143
 
 
 
2,826
 

Derivative liability

 
 
833
 
 
 
1,785
 

Total current liabilities

 
 
7,246
 
 
 
8,746
 

Total liabilities

 
 
7,246
 
 
 
8,746
 

Commitments and contingencies (Note 7)

 
 
–
 
 
 
–
 

Stockholders' deficit:

Convertible preferred stock, undesignated, par value $.0001 per share; 29,986,846 shares authorized, no shares issued and outstanding, respectively

 
 
–
 
 
 
–
 

Convertible preferred stock Series A, par value $.0001 per share; 1,854 shares authorized, 134 shares issued and outstanding, respectively

 
 
–
 
 
 
–
 

Convertible preferred stock Series B, par value $.0001 per share; 1,000 shares authorized, 71 shares issued and outstanding, respectively

 
 
–
 
 
 
–
 

Convertible preferred stock Series C, par value $.0001 per share; 300 shares authorized, 290 shares issued and outstanding, respectively

 
 
–
 
 
 
–
 

Convertible preferred stock Series D, par value $.0001 per share; 5,000 shares authorized, 5,000 shares issued and outstanding, respectively

 
 
–
 
 
 
–
 

Convertible preferred stock Series E, par value $.0001 per share; 5,000 shares authorized, 5,000 shares issued and outstanding, respectively

 
 
 
 
 
 
–
 

Common stock, par value $.0001 per share; 150,000,000

 
 
–
 
 
 
–
 

shares authorized, 40,490,657 and 623,382 shares issued and outstanding, respectively

 
 
4
 
 
 
–
 

Additional paid-in capital

 
 
53,258
 
 
 
51,957
 

Accumulated deficit

 
 
(60,475
)
 
 
(60,680
)

Total stockholders' deficit

 
 
(7,213
)
 
 
(8,723
)

Total liabilities and stockholders' deficit

 
$
33
 
 
$
23
 

INSPYR THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF LOSSES
(unaudited)
(in thousands, except share and per share data)

 
Three Months Ended September 30,
 
 
Nine Months Ended
September 30,
 

 
2020
 
 
2019
 
 
2020
 
 
2019
 

Operating expenses:

Research and development

 
$
11
 
 
$
11
 
 
$
33
 
 
$
33
 

General and administrative

 
 
126
 
 
 
126
 
 
 
344
 
 
 
466
 

Total operating expenses

 
 
137
 
 
 
137
 
 
 
377
 
 
 
499
 

Loss from operations

 
 
(137
)
 
 
(137
)
 
 
(377
)
 
 
(499
)

Other income (expense):

Gain on change in fair value of derivative liability

 
 
2,024
 
 
 
959
 
 
 
353
 
 
 
640
 

Gain on conversion of debt

 
 
240
 
 
 
–
 
 
 
398
 
 
 
50
 

Interest expense, net

 
 
(21
)
 
 
(401
)
 
 
(169
)
 
 
(683
)

Income (loss) before provision for income taxes

 
 
2,106
 
 
 
421
 
 
 
205
 
 
 
(492
)

Provision for income taxes

 
 
–
 
 
 
–
 
 
 
–
 
 
 
–
 

Net income (loss)

 
$
2,106
 
 
$
421
 
 
$
205
 
 
$
(492
)

Net income (loss) per common share, basic

 
$
0.16
 
 
$
1.75
 
 
$
0.03
 
 
$
(2.08
)

Net income (loss) per common share, diluted

 
$
(0.00
)
 
$
(0.07
)
 
$
(0.00
)
 
$
(2.08
)

Weighted average shares outstanding, basic

 
 
13,344,461
 
 
 
240,000
 
 
 
6,818,722
 
 
 
237,070
 

Weighted average shares outstanding, diluted

 
 
542,003,815
 
 
 
2,047,302
 
 
 
535,478,076
 
 
 
237,070
 

About Inspyr Therapeutics, Inc.
Inspyr Therapeutics, Inc. is a pharmaceutical company focused on the research and development of novel targeted precision therapeutics for the treatment of cancer. Our approach utilizes our proprietary delivery technology to better enhance immuno-modulation for improved therapeutic outcomes. Our potential first-in-class immune-oncology lead asset, RT-AR001, an adenosine receptor antagonist, is differentiated by its novel microparticle formulation that allows for better tumor infiltration and enhanced outcomes when administered intra-tumorally. Our patented portfolio of adenosine receptor antagonists provides flexibility to optimize treatment based on the specific targets found in each type of cancer.

Cautionary Statement Regarding Forward-Looking Information:
This news release contains "forward-looking statements" made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "seek" or "will." Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Inspyr Therapeutic's periodic reports filed with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Reports on Form 10-Q as well as and in other reports filed with the SEC. We do not assume any obligation to update any forward-looking statements.

CONTACT:

inspyrinfo@gmail.com

SOURCE: Inspyr Therapeutics, Inc.

ReleaseID: 618049

SINGAPORE / ACCESSWIRE / November 24, 2020 / Swapping cryptos on an exchange can be incredibly inefficient, as no exchange has all the coins in one fold. VaultSwap a project by Jason Wright, which is also the CEO zenomatrix.net, intends to proffer a solution to this problem. It has several high-paying investment schemes that reward investors for their confidence in the project.

What Is VaultSwap?

VaultSwap is a blockchain-powered exchange and Yield Farming where users can swap one cryptocurrency for another. VaultSwap is completely decentralized, as it also supports staking applications. Some of the groups that will receive VAULT after the token sale are Pre-Sale, Staking platform, as well as Exchange listings.

The team behind VaultSwap comprise of technocrats who understand the dynamics in the asset swapping ecosystem. The team has a track record of delivering on their promises.

Where to Buy VAULT Tokens

The VAULT tokens sale is live. The sales started on November 20th and will end on December 20th. The maximum supply is 200,000 VAULT with 5,000 ETH hard cap. The team behind VaultSwap has also announced that VAULT will be listed on P2Pb2b. More listings are expected in the coming weeks.

Token Sale Link

Interested in buying VAULT tokens? Then visit https://vaultswap.io/#token-section to get started.

Steps to Buy VAULT Tokens

Participating in the ongoing token sale is a breeze. Kindly follow the steps below:

Send ETH to this contract address: 0x8cf4dd7aa26f00d5710b6d1c82bf6647ee2d55a9
Vault Token allocation is automatic via contract
Ensure you send ETH from an ERC20-supported wallet.
Do not send ETH from an exchange
Minimum buy is 0.1 ETH

VaultSwap Exchange Products

The following are the products offered by VaultSwap:

Staking: Instead of storing away your VAULT token in a wallet, you can stake it and be rewarded with an APR of 30%.
Lending: Some investors are seeking funding to scale their businesses. You can lend them your cryptos (USDT, USD, DAI, TUSF, PAX, and BUSD) and get up to 26% APR.
Yield Farming: Yield Farming gives you the opportunity to earn up to 2,000% APR when you contribute liquidity on the VaultSwap platform.
Referral Program: Convince your friends or family members to participate in the ongoing token sale, and you would be rewarded with 10% of the total sum that your referee invested.

VaultSwap Tokenomics

Name:VaultSwap
Max Token:200,000 VAULT
Hard Cap:5000 ETH
Price:1 ETH = 20 VAULT
Currency:ETH
Min Purchase:0.1 ETH / 2 VAULT
Starts:November 20 (9:00 AM)
Ends:December 20 (11:59 PM)
Contract address: 0x8cf4dd7aa26f00d5710b6d1c82bf6647ee2d55a9

Conclusion

VaultSwap is a blockchain-powered crypto-swapping exchange. To achieve a smooth assets-to-assets swapping, VaultSwap does not rely on synthetic assets or wrapped ERC-20 tokens. In fact, the process of swapping assets on the VaultSwap platform is pretty easy and doesn't exceed 5 steps.

Users don't need any special wallet or software to swap their coin. The basic thing users need is a strong internet connection, an asset, a wallet address, and a good browser. VaultSwap Exchange does not charge a fee to swap from one crypto to the other.

Media contact:

Company: Vault.ltd
Contact: Jason Wright
Support Contact: ceo@vaultswap.io
Telephone: +17026232463
Telegram: https://t.me/VaultSwap
Twitter: https://twitter.com/Vault_Swap
Website: https://vaultswap.io/

SOURCE: Vault.ltd

ReleaseID: 618203

LOS ANGELES, CA / ACCESSWIRE / November 24, 2020 / Compare-autoinsurance.org (https://compare-autoinsurance.org) is a top auto insurance brokerage website, providing car insurance quotes online from trustworthy agencies all over the United States. This website has recently launched a guide that presents the most valuable car insurance discounts and how to get them.

To obtain cheaper car insurance, drivers should take advantage of the discounts that are available for them. Car insurance companies are known to offer discounts for various reasons. However, only a few are capable to significantly lower the price of auto insurance.

The most valuable discounts, that can help the drives lower their insurance policies the most, are the following:

Multi-policy discount. Also called bundling, this type of discount is one of the most rewarding. Policyholders can get significant savings by insuring house and car together to one insurance company. Multi-vehicle plans can also provide significant savings. Depending on the number of combined policies and the value of the insured belongings, the value of the discount can be pretty high. Some insurers can offer a discount as large as 20% of the value of the whole bundled package.
Low-mileage discount. Policyholders that moved closer to their workplace, or retired, should ask their insurers if they are eligible for this discount. Drivers that drive fewer miles than a certain amount are eligible for this type of discounts. Depending on the insurance company, this discount can be as high as 20%.
Good driver discount. Drivers that manage to keep a clean driving record for a number of years can be rewarded with a discount from their insurers. Depending on the insurance companies, drivers will have to keep their driving records clean for a period that ranges from three to five years.
Good student discount. Insurance companies think teenagers are hazardous drivers. Teenagers tend to be more reckless than other drivers and are also less experienced, so even the responsible ones are rarely given the benefit of the doubt. However, insurers often provide discounts to students who maintain a 3.0 GPA in school.
Safety gear discount. Insurance companies will reward those car owners that are willing to make their cars safer. Policyholders should check with their insurers and see what safety devices are approved. Safety devices like anti-lock brakes, GPS tracking systems, rear-view cameras, and more can potentially lower the price of insurance.

For additional info, money-saving tips, and free car insurance quotes, visit https://compare-autoinsurance.org.

Compare-autoinsurance.org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc.

"To make car insurance more affordable, insurers provide a wide range of discounts. However, only a few of these discounts can significantly lower the price of insurance", said Russell Rabichev, Marketing Director of Internet Marketing Company.

CONTACT:

Company Name: Internet Marketing Company
Person for contact: Daniel C
Phone Number: (818) 359-3898
Email: cgurgu@internetmarketingcompany.biz
Website: https://compare-autoinsurance.org

SOURCE: Internet Marketing Company

ReleaseID: 618167

SCOTTSDALE, AZ / ACCESSWIRE / November 24, 2020 / For deeper sleep and faster recovery, individuals with active lifestyles to professional athletes all depend on Zoma for its sleep-enhancing mattresses and bedding accessories. Now, as part of Zoma's Black Friday mattress sales and through until Cyber Monday, shoppers can save $150 on their memory foam mattresses and hybrid mattresses with promo code BF150.

The Zoma Mattress and Zoma Hybrid are designed with a universally comfortable medium firmness level, which is perfect for side, back and combination sleepers as well as individuals that commonly experience soreness, stiffness, and back, hip, or shoulder pain. From Zoma's temperature-regulating gel memory foam to its Triangulex™ zoned support technology and Reactiv™ response layer, the Zoma team has used its combined decades of experience in the mattress industry to construct the perfect mattress for recovery.

For Zoma's Black Friday and Cyber Monday mattress sale, customers can also buy one Zoma Sports Pillow and get the second one for 50% off with promo code BOGO50. And to elevate their sleep experience, Zoma Adjustable Beds are available for 30% off.

On all its mattresses and pillows, Zoma offers a 100 night trial and 10-year warranty. All orders come with free, no-contact delivery within the lower 48 states, and free returns are available on their mattresses and pillows. Visit ZomaSleep.com to learn more and get the performance-enhancing sleep you've always dreamed of.

Media Contact:

Zoma Sleep
pr@zomasleep.com
7167 E. Rancho Vista Drive, Suite #137
Scottsdale, Arizona 85251.USA
888-400-8856
https://zomasleep.com/

SOURCE: Zoma Sleep

ReleaseID: 617889

Not for distribution to U.S. news wire services or dissemination in the United States.

VANCOUVER, BC / ACCESSWIRE / November 24, 2020 / Silver Elephant Mining Corp. ("Silver Elephant" or the "Company") (TSX:ELEF)(OTCQX:SILEF)(Frankfurt:1P2N) is pleased to announce the closing of its bought deal short form prospectus offering pursuant to which the Company has issued 23,000,000 common shares of the Company (the "Common Shares") at a price of C$0.40 per Common Share, for aggregate gross proceeds of C$9,200,000 (the "Offering"), including the full exercise of the over-allotment option.

The Offering was led by Mackie Research Capital Corporation as lead underwriter and sole bookrunner, on behalf of a syndicate of underwriters, including Canaccord Genuity Corp. and Sprott Capital Partners LP.

The net proceeds from the Offering will be used for the exploration, development and/or improvement of the Company's mineral properties and for working capital purposes. For more information, please see the final short form prospectus of the Company dated November 17, 2020, posted on the Company's SEDAR profile at www.sedar.com.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or under any U.S. state securities laws, and may not be offered, sold, directly or indirectly, or delivered within the "United States" or to, or for the account or benefit of, persons in the "United States" or "U.S. persons" (as such terms are defined in Regulation S under the U.S. Securities Act) except in certain transactions exempt from the registration requirements of the U.S. Securities Act and all applicable U.S. state securities laws.

About Silver Elephant

Silver Elephant is a premier silver mining company. The Company's goal is to enable shareholders to own as much silver in the ground as possible.

SILVER ELEPHANT MINING CORP.

ON BEHALF OF THE BOARD

"John Lee"
Executive Chairman

For more information about Silver Elephant, please contact Investor Relations:

+1.604.569.3661 ext. 101
ir@silverelef.com
www.silverelef.com

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this news release, including statements which may contain words such as "expects", "anticipates", "intends", "plans", "believes", "estimates", or similar expressions, and statements related to matters which are not historical facts are forward-looking information within the meaning of applicable securities laws. Such forward-looking statements, which reflect management's expectations regarding the Company's future growth, results of operations, performance, and business prospects and opportunities, and the use of proceeds of the Offering are based on certain factors and assumptions and involve known and unknown risks and uncertainties which may cause the actual results, performance, or achievements to be materially different from future results, performance, or achievements expressed or implied by such forward-looking statements.

These factors should be considered carefully, and readers should not place undue reliance on the Company's forward-looking statements. The Company believes that the expectations reflected in the forward-looking statements contained in this news release and the documents incorporated by reference herein are reasonable, but no assurance can be given that these expectations will prove to be correct. In addition, although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results not to be as anticipated, estimated, or intended. The Company undertakes no obligation to publicly release any future revisions to forward-looking statements to reflect events or circumstances after the date of this news or to reflect the occurrence of unanticipated events, except as expressly required by law.

SOURCE: Silver Elephant Mining Corp.

ReleaseID: 618068

VANCOUVER, WA / ACCESSWIRE / November 24, 2020 / Adaptive Ad Systems, Inc. (OTC PINK:AATV), announced today that construction of new headquarters for its subsidiary Adaptive Broadband (ABB) will commence in the first quarter of 2021.

ABB is Adaptive's Wireless Internet Service Provider ("WISP") that provides High Speed Fixed Wireless Broadband to residences and small businesses and has established itself as experts in serving small metro and rural areas. Currently operating in select areas of Oregon covering approximately 500 square miles, ABB offers competitive internet speeds with reliable symmetrical upload and download speeds, no data limits, no contracts, and no installation charges, all at competitive prices.

ABB Vice President and General Manager Jordan Reed states: "Adaptive Broadband was recently awarded a cable television franchise in Jefferson, Oregon. In support and commitment to that award, we purchased commercial real estate in downtown Jefferson to construct our new headquarters, from which we will operate our Oregon and southern Washington broadband and video services. Construction on our new building will commence in the first quarter of 2021. This fixed-base addition to our infrastructure increases our ability to deliver broadband and video services at competitive prices in the Northwestern United States and will serve as a model for expansion into other states."

As previously reported, ABB began a network-wide infrastructure upgrade in 2019, further expanding its network of transmission towers. These upgrades were completed in 2020, which has allowed ABB to deliver internet access to rural areas that have limited affordable internet access.

J. Michael Heil, CEO of parent company Adaptive Ad Systems, states: "The real estate acquisition and upcoming construction for the headquarters of Adaptive Broadband represents our overall commitment to innovative development of services and technologies for the broadband and cable TV markets in general and delivering products and services to rural markets in particular. There are countless rural communities across America that need what we are currently developing in the Northwest and planning to branch out further beyond Oregon. Just as Amazon started in a garage in Bellevue, Washington, the beginnings of Adaptive Broadband in Jefferson, Oregon will become an evolving success story."

THE ADAPTIVE SYSTEM. Adaptive Ad Systems Inc. is a digital media and video communications company. Together with its subsidiaries and manufactures it develops and deploys Dynamic Digital Ad Insertion (DDAI) streaming media hardware and proprietary processing software for the Cable TV, Satellite, IPTV markets. Via its subsidiary Adaptive Broadband, it provides High Speed Fixed Wireless Internet Service (WISP) to residences and small businesses. The Company's DDAI and WISP services target the often-over-looked 2nd and 3rd Tier cable TV and rural WIFI markets and now also the Tier 1 markets in the US. Adaptive's proprietary software and hardware, installed in scores of cable television systems across the United States, creates a "network" of linked cable system. This allows advertisers to purchase ads across the Adaptive network, generating significant more ad impressions than through the traditional ad insertion technologies in individual systems. Adaptive Ad Systems has established an innovative revenue share agreement with each individual system and manages all ad-related activities. Currently, the Company serves over 75 designated marketing areas in over 40 states. The Adaptive Broadband network system provides services via a network of Hybrid Access Points and Micro POPs. For additional information, please visit: www.aatv.co.

FORWARD-LOOKING STATEMENTS. Any statements contained in this press release that do not describe historical facts constitute forward-looking statements. Forward-looking statements may include, without limitation, financial projections, statements regarding the plans and objectives of management for current and future operations, the development, regulatory approvals and commercialization of the Company's products, or any of the Company's proposed services, systems, services, licensing arrangements, joint ventures, partnerships or acquisitions. Such forward-looking statements are not meant to predict or guarantee actual results and performance and actual events or results may differ considerably. Factors that may cause actual results to differ materially from any projections may include, without limitation, delays in the Company's development of its products and services, the inability to obtain additional financing, the impact of significant new or changing government regulation on the industry, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's general failure to effectively implement the Company's business plans or strategies. The Company assumes no obligation to update any forward-looking statements to reflect any change in events or circumstances that may arise after the date of this release.

Adaptive Ad Systems, Inc.
4400 NE 77th Avenue Suite 275
Vancouver, Washington 98662
310-321-4958
info@aatv.co
www.aatv.co

StockWatchIndex
San Diego, California
442-287-8059
info@stockwatchindex.com
www.stockwatchindex.com
www.swiresearch.com

SOURCE: Adaptive Ad Systems, Inc.

ReleaseID: 618159

Key players are offering different grades of products and adopting inorganic and organic approaches to monopolize their brand and fortify their market position.

ROCKVILLE, MD / ACCESSWIRE / November 24, 2020 / The talc market is projected to record a steady CAGR of 3% during the assessment period, 2019-2029. The growth can be primarily attributed to the extensive use of talc in the production of lightweight automotive parts. In recent years, automotive production has increased by close to 25 Mn units and the landscape will continue to create a healthy environment for talc's market growth.

"Efficacy to reinstate mechanical attributes of recycled plastics and its aptitude to be a great nucleating agent in biopolymers is anticipated to increase the demand for talc, over the assessment period." says the Fact.MR report.

Request a report sample to gain comprehensive market insights at

https://www.factmr.com/connectus/sample?flag=S&rep_id=4479

Talc Market- Key Takeaways

East Asia to uphold its supremacy exhibiting a CAGR of 4% during the forecast period
Ceramic industry is likely to remain the key beneficiary among other end-use industries.
Talc carbonate is poised to record a skyward growth rate amid deposit types.
Powder form talc will outdo the market estimation of US $ 510 Mn towards 2029 end.

Talc Market – Driving Factors

Increased uptake of talc in engineering polymers to generate remarkable prospects in the talc market.
Growing usage of talc for automotive parts as an excellent reinforcing filler in engineering thermoplastics to bolster market growth over the forecast period.
Growing application of talc in several end-use industries owing to its excellent barrier properties and weather resistivity is boosting the sales of the talc market.

Talc Market – Constraints

Sluggish growth of pulp & paper sector due to digitalization has prompted a drop in demand for talc.
Strict guidelines regulating the manufacturing and use of talc is anticipated to hamper the growth of the talc market.

Anticipated Market Impact by COVID-19 Outbreak

The COVID-19 pandemic is slated to provide a positive growth trajectory to the talc market.

Several studies show that talc will offer long lasting skin protection to the ones wearing PPE, an advance which will help healthcare workers avert injury from prolonged usage of masks and visors amid the COVID-19 outbreak.

Explore the global Talc market with 98 figures, 74 data tables, along with the table of contents of the report. You can also find detailed segmentation on https://www.factmr.com/report/4479/talc-market

Competition Landscape

Major market players operating in the global talc market include IMI Fabi, Imerys, Jai Vardhman Khaniz Pvt. Ltd., Minerals Technologies Lianoing Aihai Talc Co. Ltd., and Mondo Minerals. Key players have been engaged in acquisitions and extension of their worldwide distribution network to fortify their market position.

More on the Report

The Fact.MR's market research report provides in-depth insights into the talc market. The market is scrutinized based on form (powdered and lumps or granules), end use industry (agriculture, ceramics, pharmaceuticals, paints & coatings, cosmetics, pulp & paper, food and others) and deposit type (talc chlorite, talc carbonate and others), across five major regions (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA)).

Explore Wide-ranging Coverage of Fact.MR's Chemical & Materials Landscape

Magnesium Nitrate Hexahydrate Market: Find insights on the magnesium nitrate hexahydrate market with analysis of segments, statistics, influencers, market players, and business strategies adopted over a 10-year forecast period.

Ferrosilicon Magnesium Market: Fact.MR's report on the ferrosilicon magnesium market offers insights on the market during 2018-2028, including restraints, revenue sources, market leaders, and market strategies.

Talc Alternatives Market: Read an analysis of the talc alternatives market with insights on growth factors, opportunities, restraints, regional market forecast, regulatory policies, and strengths of market leaders.

About Fact.MR

Fact.MR is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. Fact.MR is headquartered in Dublin, and has offices in Dubai. Fact.MR's latest market research reports industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.

Contact:

Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
PR- https://www.factmr.com/media-release/1257/global-talc-market

SOURCE: FactMR

ReleaseID: 618194